中国神经再生研究(英文版) ›› 2018, Vol. 13 ›› Issue (12): 2102-2104.doi: 10.4103/1673-5374.241458

• 观点:退行性病与再生 • 上一篇    下一篇

鼻-脑给药方式:是治疗阿尔茨海默病的关键

  

  • 收稿日期:2018-08-08 出版日期:2018-12-15 发布日期:2018-12-15

Nose-to-brain drug delivery approach: a key to easily accessing the brain for the treatment of Alzheimer’s disease

Amit Alexander1, Shailendra Saraf2, 3   

  1. 1 Rungta College of Pharmaceutical Sciences and Research, Bhilai, Chhattisgarh, India;
    2 Durg University, Govt. Vasudev Vaman Patankar Girls’ P.G. College Campus, Raipur Naka, Durg, Chhattisgarh, India;
    3 University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur, Chhattisgarh, India
  • Received:2018-08-08 Online:2018-12-15 Published:2018-12-15
  • Contact: Shailendra Saraf, PhD, shailendrasaraf@rediffmail.com.

摘要:

orcid: 0000-0002-8384-9370 (Shailendra Saraf)

Abstract:

Alzheimer’s disease (AD): AD, a neurodegenerative disorder and a significant cause of dementia throughout the world mostly affects the older adults but sometimes also seen in young age (early state AD). As per the Alzheimer Association report 2017, AD remains to be considered as the 6th leading cause of death which nearly touches around 5.5 million people only in the USA and the data is similar throughout the world (approximately 37 million people suffers from AD). On the other hand, the treatments are insufficient, and the available therapies do not claim the complete cure of disease. Instead, they relieve the symptoms in the preliminary stage. Also, AD therapies are very costly, mostly unaffordable for an average income population. Such constraint is due to the inaccessibility of the brain. The human brain is the most complex and delicate organ, highly protected by various physiological shields primarily the blood-brain-barrier (BBB). The BBB upholds the homeostasis of the brain and restricts the entry of most of the foreign components including lipids, peptides, and essential nutrients. Thus, the entry of almost all the drugs and bioactive to the brain remains complicated. The intranasal (IN) route offers an alternative approach for drug delivery to the brain without the interference of the BBB. In our previous article, we have discussed various innovative approaches, describing the novel techniques, efficiency, limitations, clinical investigations, patents, FDA status, current scenario and future possibilities of direct noseto-brain drug delivery.